Table 2.

Results of the Age-Adjusted Proportional Hazards Regression of the Effect of Statin Use on AMD progression based on AMD Subtype: Hazard Ratios and 95% Confidence Limits for Unmatched for Statin Use Propensity Scores.

	All participants N=3791		Bilateral Large Drusen N = 2462		Unilateral Late AMD N = 1329
	Hazard Ratio	95% CI	Hazard Ratio	95% CI	Hazard Ratio	95% CI
Any late age-related macular degeneration
Without accounting for the competing risk of death	1.08	0.83–1.41	1.00	0.72–1.41	1.20	0.79–1.83
Accounting for the competing risk of death	0.94	0.72–1.22	0.84	0.60–1.18	1.08	0.71–1.65
Any geographic atrophy
Without accounting for the competing risk of death	1.21	0.85–1.73	1.13	0.74–1.73	1.42	0.74–2.73
Accounting for the competing risk of death	1.06	0.74–1.51	0.96	0.62–1.48	1.29	0.66–2.49
Central geographic atrophy
Without accounting for the competing risk of death	1.08	0.67–1.74	1.03	0.59–1.80	1.24	0.49–3.16
Accounting for the competing risk of death	0.92	0.57–1.48	0.85	0.48–1.49	1.14	0.45–2.87
Neovascular age-related macular degeneration
Without accounting for the competing risk of death	1.24	0.89–1.73	1.34	0.86–2.09	1.11	0.66–1.86
Accounting for the competing risk of death	1.07	0.80–1.50	1.12	0.73–1.74	1.00	0.60–1.67

CI = confidence interval.